Azịza ngwa ngwa
Nitrosamine risk in peptide manufacturing is a per-product conclusion, not a category assumption. Karịrị 1,800 drug-product batches have been recalled in th…
Kedu ihe kpatara ihe egwu nitrosamine ji bụrụ ngwaahịa kpọmkwem karịa otu echiche zuru ụwa ọnụ
Synthesis nke Polypeptide Supplier Pseudoproline Synthesis Achọrọ nyocha ihe egwu nitrosamine akọwapụtara nke ngwaahịa n'ihi na oriri a na-anabata na-adabere na nhazi nitrosamine nke ọ bụla., na ahịrị ndị dị ize ndụ na-adabere na njikọ nke onye ọ bụla. Nkọwa FDA nke usoro ike-categorisation na-ekwu na NDSRI bụ ihe pụrụ iche maka ọgwụ ọ bụla yana na ọ naghị enwekarị data nchekwa dị iji guzobe oke AI., ya mere a na-enyocha ihe owuwu nke ọ bụla n'otu n'otu site na chaatị na-erugharị na-ekenye ụdị ike. Nke ahụ bụ ọkara toxicological nke arụmụka ahụ.
Ọkara usoro bụ na ntule bụ nke onye ji ikike ịzụ ahịa na-arụ ọrụ na API na ndị na-emepụta ngwaahịa na ndị na-ebubata ngwa ahịa ha., iji ụkpụrụ njikwa ihe egwu dị mma dịka akọwapụtara na ICH Q9, yana na ihe egwu achọpụtara na API ma ọ bụ ngwaahịa emechara na-ebute ule nkwenye n'egbughị oge, kwa Nitrosamine nke EMA&A (Mkpu.23, October 2025). Ihe si na ya pụta bụ na ọ nweghị otu ọnụọgụ nwere ike ịhota n'ofe pọtụfoliyo peptide.
Ọnụọgụ ndị ahụ na-agbanwe site na ikike, na ndịiche dị ukwuu n'ụdị kachasị ike. Tebụl oriri FDA na-anabata maka nitrosamines na-enye 100 nke/ụbọchị maka CPCA Atiya 2, 400 nke/ụbọchị maka Category 3, na 1,500 ng/ụbọchị maka Categories 4 na 5, mgbe Ntuzi aka nitrosamine nke Canada na-edepụta udi 1 na 18 ng/ụbọchị na Categories 2 site na 5 na 100, 400, 1,500 na 1,500 nke/ụbọchị. Tebụl abụọ ahụ kwekọrịtara na ngalaba 2 elu, yabụ iwu bara uru bụ ịkpọ aha ikike na ọnụ ọgụgụ ọ bụla karịa nkezi ha.
Kedu ihe ntinye na-emepụta peptide nwere ike iwebata ihe egwu nitrosamine n'ezie
Map nwere ike ịmepụta na ụzọ mmetọ: amine na-adịghị ike ma ọ bụ precursors, ndị ọrụ nitrosating, mmeghachi omume na ọnọdụ nchekwa, ihe ejigharịgharịa, mmetọ cross na ibufe nitrosamines preformed. Enweghị amine na ngwaahịa e zubere anaghị ewepu n'onwe ya mmetọ nitrosamine.
Akụkụ nitrosating nke ihuenyo bụ ndepụta akọwapụtara. Usoro ọrụ njikwa ihe egwu nke EFPIA aha nitrites dị ka sodium nitrite na nitrous acid, nitric oxide, nitrosyl halides, Dinitrogen trioxide na dinitrogen tetroxide, na organic nitrites dị ka tert-butyl nitrite. Otu usoro a na-arụ ọrụ na-ekwu na nitrite abụghị n'onwe ya bụ ihe nitrosating kama ọ nwere ike ịghọ otu n'okpuru ọnọdụ dịka mgbasa ozi acidic., ihe dị iche kwesịrị iburu n'ime ndekọ ahụ ka onye nlegharị anya anaghị ewere aha nitrite ọ bụla dị ka nchọpụta akpaka.
Ndepụta amine na-adịghị ike bụ ebe usoro peptide dị iche na usoro obere-molecule. Usoro ọrụ njikwa ihe egwu nke EFPIA aha amines ewepụtara dị ka adịghị ọcha ma ọ bụ mmebi nke ihe mgbaze amide DMF, DMac na NMP; Amine nke atọ bụ triethylamine, diisopropylethylamine (DIPEA) na N-methylmorpholine (NMM); quaternary ammonium salts dị ka tetrabutylammonium bromide; na ndị isi amines dị ka monoethylamine. Ọ na-egosipụtakwa ntinye siri ike dị ka NaCl, NaOH, K2CO3 na unyi nwere ike ibu ọkwa ppm nke ihe nitrosating, mgbe mmiri mmiri reagent, A na-ewerekarị ihe mgbaze organic na mmiri pH dị ala na-enweghị nitrite.
Usoro ahụ abụghị n'echiche. Nyochaa ihe omume nitrosamine edekọtara na-achọpụta NDMA na valsartan gaa na dimethylamine dị ka ihe na-emerụ emerụ na DMF., NMBA na-ebu ụzọ mebie NMP, na NDIPA na NEIPA na dealkylation ngwaahịa nke DIPEA. WHO GMP mgbakwunye na nitrosamines na-esetịpụ oke na ọkwa nke ụzọ njikọ, ihe, ihe mgbaze na akụrụngwa, nke bụ granularity nke ihuenyo ntinye peptide chọrọ.
Kedu ka ọnọdụ usoro si agbanwe ihe egwu ahụ
Ọnọdụ atọ ndị na-eme ka amine dị ugbu a ghọọ nitrosamine kpụrụ bụ amine na-adịghị ike, ụdị nitrosating, na ọnọdụ ndị na-ejikọta ha ọnụ. Nke Synthetic Polypeptide Supplier WHO GMP mgbakwunye na nitrosamines na-ekwu na a ga-ezere iji nitrite ma ọ bụ onye na-ahụ maka nitrosating ọzọ dị ka ihe na-emenyụ ọkụ ma ọ bụrụ na amines na-adịghị ike nwere ike ịnọ na nke ahụ ma ọ bụ usoro usoro ọzọ na njedebe zuru oke adịghị ekwe nkwa., ma ọ na-akwado dochie nitrites na azide decomposition quenches.
Nzọụkwụ nkwụsị ahụ bụ ọnọdụ ọdịda edekọtara. Nyochaa ihe omume nitrosamine edekọtara na-akọwa otu esi ewepụ azides na-emeghị eme site na nhazi tetrazole site na ịgbakwunye sodium nitrite na gburugburu acid., na na alkyl amine ọ bụla na-esi na ihe mgbaze, reagents ma ọ bụ mmetọ nke dị n'elu nwere ike ịmepụta nitrosamines metụtara n'oge ọnọdụ ahụ. Otu nyocha ahụ na-akọwa metformin dị ka ihe kwụsiri ike ma na-achọ ndị nnọchi anya nitrosating, mmiri na okpomọkụ, ya na nitrites na nitrates na ihe mgbakwunye gbakwunyere mmiri granulation mmiri na ikpo ọkụ na-amalite nitrosation..
Ihe ize ndụ ahụ anaghị akwụsị na ụzọ njikọ. EMA's nitrosamine Q&A (Mkpu.23, October 2025) gbakwunyere ihe ize ndụ nke ịmepụta nitrosamine site na ihe ndị na-arụ ọrụ ma ọ bụ adịghị ọcha ha metụtara nke nwere amine na-adịghị ike n'oge nhazi ngwaahịa na nchekwa n'ihi akara nitrites., ma gwa ndị MAH ndị na-atụleghị nke a na nzọụkwụ 1 tugharia nlebanya ha wee gaba n'iru n'usoro 2 ule dị ka o kwesịrị. Maka onye na-emepụta peptide, nke ahụ pụtara quench reagent, stoichiometry ya, pH na usoro nke mgbakwunye na-edekọ mgbanwe, na otú ihicha, nchekwa na nkwakọ ngwaahịa. Ntụle na-akwụsị na ụzọ njikọ na-eruteghị usoro ndị ahụ na-ahapụ ọnọdụ ọdịda na-enyochaghị ya, nke bụ ebe nyocha ihe egwu nitrosamine maka nrụpụta peptide kwụsịrị ịbụ ihe a ga-agbachitere.
Ụzọ njikọ ahụ ọ na-agbanwe ntule
Ee, ụzọ na-agbanwe nke klaasị reagent na-abanye na ntule, mana ọ naghị agbanwe usoro ntule. Usoro ọrụ njikwa ihe egwu nke EFPIA Nkebi nke amine na nitrosating-agent isi mmalite site reagents, A na-eji ihe mgbaze na ihe mgbaze eme ihe, ya mere, ụzọ na-ekpebi ndepụta ntinye karịa nkwubi okwu.
Na SPPS, nyochaa ezigbo ntọala, ihe mgbaze, adịghị ọcha na iyi mgbake. Piperidine, A na-ejikarị ewepu Fmoc, bụ secondary amine; DIPEA eji na njikọta bụ amine tertiary. Ọdịdị ha na ụzọ mmeghachi omume ha dị iche, ya mere akọwala ebe nchekwa na njikọ njikọ dịka amines nke atọ.
Maapụ ụzọ na-ekpebikwa onye nwere ndekọ. Bachem's SPPS kpọmkwem nitrosamine webinar nleba ihe egwu dobe CDMO dị ka onye nche ọnụ ụzọ maka mmetọ nitrosamine n'etiti ihe mmalite na nhazi ọgwụ, nke bụ interface ebe akwụkwọ ndị na-eweta peptide ga-ewepụ ya nke ọma Ngwakọta Peptoid siri ike ka emechara ngwaahịa. Ntuziaka EMA na peptides sịntetik na-enye akwụkwọ echere maka API peptide sịntetik, gụnyere ihe mmalite, reagents na adịghị ọcha, yabụ enwere ike wulite faịlụ nitrosamine dị ka ndọtị nke faịlụ CMC karịa mmega ahụ yiri ya.
Kedu njikwa nyocha na nyocha nkwenye ka ntule chọrọ
Usoro nkwenye zuru oke naanị mgbe oke ọnụọgụ ya nọ na ma ọ bụ n'okpuru ọkwa ị ga-ejikwa, na mgbe ngwugwu nkwado ya kpuchiri matriks ị na-agba ọsọ. I Q2(R2) na-achọ ka maka ule adịghị ọcha, QL maka usoro nyocha ahụ hà nhata ma ọ bụ n'okpuru ebe mkpesa., ọ na-achọkwa nkọwapụta, oke, izi ezi, nkwughachi na nzizi etiti maka ule adịghị ọcha nke ọnụọgụ. Otu ntụzịaka ahụ na-akọwa oke ngụta dị ka ọnụọgụ nyocha kacha ala na nlele nke enwere ike ikpebi ọnụọgụgụ yana nkenke na izi ezi kwesịrị ekwesị..
<klas ọgụgụ ="blọọgụ-akara ngosi" ụdị ="oke-obosara:640px;oke:1.5rem akpaaka;font-nha:12px;ahịrị-ịdị elu:1.3;agba:eketa"> <svg viewBox="0 0 560 380" ụdị ="oke-obosara: 100%; elu: akpaaka; font-ezinụlọ: 'Inter', usoro-ui, sans-serif; agba: #1e293b; --chaatị-mechiri emechi: #64748b;" ọrụ ="img" aria-labeledby="nitrosamine-usoro-uche-vs-chọrọ-oke-aha nitrosamine-usoro-uche-vs-chọrọ-oke-desc"> <ịke> /* Onye nrụpụta na-etinye eserese ahụ n'ime iframe nke ihe ndabere ya dị oji, na iframe bụ ọdịdị dị iche na chaatị ahụ, ya mere eriri igbe akwụkwọ ozi gosipụtara dị ka okpokolo agba gbara ya gburugburu (prod 09-22). Akwụkwọ dị n'ime iframe pụtara ìhè na ndabara; esere ya ebe a na-ekpuchi ndabere elementrị, na mgbe e debere chaatị ahụ kama nke a dabara na ihe ọ bụla. Debe brackets n'akuku na ngọngọ a: A na-atụgharị akụkụ ụdị n'ime SVG dị ka ọdịnaya nke mba ọzọ, ya mere otu nkwado kpafuru akpafu na-atụfu iwu niile dị na ya. */ html, ahu { ndabere: #fffff; oke: 0; } @mgbasa ozi (na-ahọrọ-ebelata-mmegharị: belata) { * { animation: onweghi !mkpa; mgbanwe: onweghi !mkpa; } } </ịke> <ziri ezi x="0" y="0" obosara ="560" elu ="380" rx="8" juru ="#fffff" /> <aha id="nitrosamine-usoro-uche-vs-chọrọ-oke-aha">Usoro nitrosamine nwere uche vs oke achọrọ</aha> <desc id ="nitrosamine-usoro-uche-vs-chọrọ-oke-desc">Usoro nitrosamine nwere uche vs oke achọrọ: ụkpụrụ maka GC-MS/MS, LC-MS/MS (ala), LC-MS/MS (elu), FDA LC-HRMS, Sitagliptin NDSRI. Usoro nitrosamine nwere uche vs oke achọrọ. data mgbochi kwụ ọtọ: GC-MS/MS 0.005; LC-MS/MS (ala) 0.01; LC-MS/MS (elu) 0.02; FDA LC-HRMS 0.05; Sitagliptin NDSRI 0.1; Amachi na 300 mg/ụbọchị 0.088.Isi mmalite: EMA Q&A, EMA/409815/2020 Mkpu.23 2025-10-10.</desc> <ederede x ="280.0" y="29" ederede-arịlịka ="etiti" font-size ="18" font-arọ="800" juru ="Agba ugbu a">Usoro nitrosamine nwere uche vs oke achọrọ</ederede> <ahịrị x1="145" y1="298.0" x2="510" y2="298.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="243.0" x2="510" y2="243.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="188.0" x2="510" y2="188.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="133.0" x2="510" y2="133.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="78.0" x2="510" y2="78.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ederede x ="136.0" y="97.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">GC-MS/MS</tsp></ederede> <ziri ezi x="145" y="78.0" obosara ="1.8" elu ="30.0" rx="4" juru ="#f97316" /> <ederede x ="154.8" y="97.5" font-size ="11" juru ="Agba ugbu a">0.005</ederede> <ederede x ="136.0" y="135.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">LC-MS/MS (ala)</tsp></ederede> <ziri ezi x="145" y="116.0" obosara ="3.6" elu ="30.0" rx="4" juru ="#38bdf8" /> <ederede x ="156.7" y="135.5" font-size ="11" juru ="Agba ugbu a">0.01</ederede> <ederede x ="136.0" y="173.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">LC-MS/MS (elu)</tsp></ederede> <ziri ezi x="145" y="154.0" obosara ="7.3" elu ="30.0" rx="4" juru ="#nke 78bfa" /> <ederede x ="160.3" y="173.5" font-size ="11" juru ="Agba ugbu a">0.02</ederede> <ederede x ="136.0" y="211.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">FDA LC-HRMS</tsp></ederede> <ziri ezi x="145" y="192.0" obosara ="18.2" elu ="30.0" rx="4" juru ="#22c55e" /> <ederede x ="171.2" y="211.5" font-size ="11" juru ="Agba ugbu a">0.05</ederede> <ederede x ="136.0" y="249.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">Sitagliptin</tsp><otu x ="136.0" dy="12">NDSRI</tsp></ederede> <ziri ezi x="145" y="230.0" obosara ="36.5" elu ="30.0" rx="4" juru ="#ihu15" /> <ederede x ="189.5" y="249.5" font-size ="11" juru ="Agba ugbu a">0.1</ederede> <ederede x ="136.0" y="287.5" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">Oke na 300</tsp><otu x ="136.0" dy="12">mg / ụbọchị</tsp></ederede> <ziri ezi x="145" y="268.0" obosara ="32.1" elu ="30.0" rx="4" juru ="#fb7185" /> <ederede x ="185.1" y="287.5" font-size ="11" juru ="Agba ugbu a">0.088</ederede> <ederede x ="280.0" y="366" ederede-arịlịka ="etiti" font-size ="10" juru ="anyi(--chaatị-mechiri emechi, Agba ugbu a)">Isi mmalite: EMA Q&A, EMA/409815/2020 Mkpu.23 (2025-10-10)</ederede> </svg> </ọgụgụ>
Site na AI na ng/ụbọchị yana oke kwa ụbọchị M na mg / ụbọchị, AI/M na-enye ntinye uche na ng/mg, ọnụọgụgụ hà nhata ppm. Ekwuru na pb, jiri uru ahụ mụbaa 1,000. Ngalaba steeti n'ụzọ doro anya ma tinye iwu ndị akọwapụtara ikike ugbu a maka otutu nitrosamines., omission ma ọ bụ belata ule.
Ịrụ ọrụ usoro ebipụtara na-enye gị oke nrịbama. A 2025 nyochaa usoro nyocha nitrosamine na-achịkọta ụzọ LC-MS/MS enyochala na 0.05 ppm, Ụzọ GC-MS/MS dị obere ka 0.001 ppm, na usoro FDA LC-HRMS na 1 nke/ml, ya na NDMA na NDEA gburugburu 0.1 ka 0.5 ng/ml na a 5 mg/ml ndabere sample ndabere. Ọnụọgụ ndị ahụ sitere na API obere molecule na sartan matrices, ya mere, ha bụ benchmark, adịghị arụ ọrụ nke peptide: peptide-matrix LOQ dabere na mmetụta matriks, nkwadebe sample na polarity nke lekwasịrị anya, and no published nitrosamine LOQ measured in a peptide drug-substance matrix was located for this article. State the matrix with every LOQ you cite.
Testing cadence follows the risk conclusion. EMA's nitrosamine Q&A (Mkpu.23, October 2025) sets testing at 10% of annual batches or 3 per year, whichever is higher, where the source of risk is understood and levels are consistent batch to batch, and requires all batches to be tested where fewer than three are made annually. The MHRA’s list of common nitrosamine submission gaps names inadequate sensitivity of analytical methods and incomplete risk evaluation among the defects it rejects, which is why the nitrosamine risk evaluation checklist should carry the method’s LOQ, its matrix and its validation status as separate line items.
Kedu ndekọ na-eme ka nkwubi okwu a na-enyocha maka onye nyocha ma ọ bụ onye na-achịkwa
Ndekọ ndekọ nke na-adịgide ndụ nyocha bụ nke na-egosipụta ogige ndebiri gọọmentị, n'ihi na nke ahụ bụ ihe onye nyocha na-atụnyere. Nlebanya nleba anya ihe egwu CMDh nitrosamine chọrọ aha na adreesị MAH; ụdị ngwaahịa; ngwaahịa na API ma ọ bụ aha etiti; nọmba ikike ịre ahịa; Nọmba usoro EU maka ngwaahịa MRP ma ọ bụ DCP; aha na adreesị onye nrụpụta API; aha na adreesị onye nrụpụta ngwaahịa emechara; usoro iheomume nkwenye-nnwale; gbakwunyere ihe ize ndụ nkewa nke elu, agafeghị oke ma ọ bụ dị ala na ngalaba ihe kpatara na-ekpuchi nrụpụta ma ọ bụ mmetọ obe, nhazi ngwaahịa ma ọ bụ nkwụsi ike, ngwaahịa njikọ, na nguzobe in-vivo. Faịlụ ndị na-eweta peptide kwesịrị inwe ike ibupụta nke ọ bụla n'ime ubi ndị ahụ maka akụkụ API..
Mgbakọ akwụkwọ na-eme ka mpaghara ndị ahụ bụrụ ihe a na-agbachitere bụ otu ihe ahụ metụtara ndekọ ọ bụla. Ekwesịrị inyocha asambodo nyocha dị ka ndekọ akọwapụtara nke ọma karịa nkwupụta azụmaahịa izugbe, na pasent nke ịdị ọcha naanị anaghị ewepụta njirimara ngwakọta zuru oke: ịdị ọcha, njirimara, usoro, nọmba nza na akwụkwọ kwesịrị ijikọ ọnụ. WHO GMP mgbakwunye na nitrosamines na-agbakwụnye ndekọ ihe ndekọ ọkọnọ ọ na-atụ anya ka echekwa ya, gụnyere aha onye na-emepụta akụrụngwa na onye na-ebu ya, ọrụ nke ndị na-emepụta ihe n'ezie, na ndị nrụpụta na ndị na-ekesa ihe ọ bụla na-ejikwa ihe ndị ahụ tupu imepụta API.
Akwụkwọ ndị na-eweta ngwaahịa anaghị emechi ajụjụ ahụ n'onwe ya. Ntuzi aka nitrosamine nke Canada na-ekwu na nkwupụta ndị nrụpụta na ndị na-ebubata ngwaahịa abụghị ihe nnọchi maka ntule ihe egwu zuru oke nke MAH., na Nitrosamine nke EMA&A (Mkpu.23, October 2025) tinye ọrụ na MAH iji soro ndị na-eweta API rụọ ọrụ iji hụ na ịdị mma API anabatara, gụnyere oke amine siri ike karịa monograph pharmacopoeial ebe ngwaahịa emechara chọrọ ha. Nkwupụta onye na-eweta ngwaahịa bụ ntinye na faịlụ ahụ, ọ bụghị nkwubi okwu ya.
Kedu mgbe a chọrọ nyocha nkwenye na mgbe nyocha na-adịghị mma edepụtara na-emechi ajụjụ a
<klas ọgụgụ ="blọọgụ-akara ngosi" ụdị ="oke-obosara:640px;oke:1.5rem akpaaka;font-nha:12px;ahịrị-ịdị elu:1.3;agba:eketa"> <svg viewBox="0 0 560 380" ụdị ="oke-obosara: 100%; elu: akpaaka; font-ezinụlọ: 'Inter', usoro-ui, sans-serif; agba: #1e293b; --chaatị-mechiri emechi: #64748b;" ọrụ ="img" aria-labeledby="nnwale-nnwale-ebum-mgbe-ihe egwu-a-amata-aha-nkwado-ule-ibu-mgbe-ihe egwu-bụ-amata-desc"> <ịke> /* Onye nrụpụta na-etinye eserese ahụ n'ime iframe nke ihe ndabere ya dị oji, na iframe bụ ọdịdị dị iche na chaatị ahụ, ya mere eriri igbe akwụkwọ ozi gosipụtara dị ka okpokolo agba gbara ya gburugburu (prod 09-22). Akwụkwọ dị n'ime iframe pụtara ìhè na ndabara; esere ya ebe a na-ekpuchi ndabere elementrị, na mgbe e debere chaatị ahụ kama nke a dabara na ihe ọ bụla. Debe brackets n'akuku na ngọngọ a: A na-atụgharị akụkụ ụdị n'ime SVG dị ka ọdịnaya nke mba ọzọ, ya mere otu nkwado kpafuru akpafu na-atụfu iwu niile dị na ya. */ html, ahu { ndabere: #fffff; oke: 0; } @mgbasa ozi (na-ahọrọ-ebelata-mmegharị: belata) { * { animation: onweghi !mkpa; mgbanwe: onweghi !mkpa; } } </ịke> <ziri ezi x="0" y="0" obosara ="560" elu ="380" rx="8" juru ="#fffff" /> <aha id="nkwenye-nnwale-ibu-mgbe-ihe ize ndụ-bụ-aha-aha">Ibu nnwale nkwenye mgbe achọpụtara ihe egwu</aha> <desc id ="ihe nnwale-nwale-ibu-mgbe-ihe ize ndụ-bụ-achọpụtara-desc">Ebe achọpụtara ihe ize ndụ, EMA na-atụ anya ịnwale 10% of annual batches or 3 per year, whichever is higher, na batches niile mgbe obere karịa 3 a na-eme kwa afọ. Ibu nnwale nkwenye mgbe achọpụtara ihe egwu. data lollipop: Obere karịa 3 batches / afọ 3; 10% nke batches kwa afọ 10; Opekempe kwa afọ 3.Isi iyi: EMA Q&A, EMA/409815/2020 Mkpu.23, Q&A 8 2025-10-10.</desc> <ederede x ="280.0" y="29" ederede-arịlịka ="etiti" font-size ="18" font-arọ="800" juru ="Agba ugbu a">Ibu nnwale nkwenye mgbe achọpụtara ihe egwu</ederede> <ahịrị x1="145" y1="298.0" x2="510" y2="298.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="243.0" x2="510" y2="243.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="188.0" x2="510" y2="188.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="133.0" x2="510" y2="133.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="145" y1="78.0" x2="510" y2="78.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ederede x ="136.0" y="118.7" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">Ihe na-erughị 3</tsp><otu x ="136.0" dy="12">batches / afọ</tsp></ederede> <ahịrị x1="145" y1="114.7" x2="254.5" y2="114.7" ọrịa strok ="Agba ugbu a" opacity="0.15" obosara-strok="1" /> <okirikiri cx="254.5" cy="114.7" r="6" juru ="#f97316" /> <ederede x ="266.5" y="118.7" font-size ="11" juru ="Agba ugbu a">3</ederede> <ederede x ="136.0" y="192.0" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">10% nke kwa afọ</tsp><otu x ="136.0" dy="12">ogbe</tsp></ederede> <ahịrị x1="145" y1="188.0" x2="510.0" y2="188.0" ọrịa strok ="Agba ugbu a" opacity="0.15" obosara-strok="1" /> <okirikiri cx="510.0" cy="188.0" r="6" juru ="#38bdf8" /> <ederede x ="522.0" y="192.0" font-size ="11" juru ="Agba ugbu a">10</ederede> <ederede x ="136.0" y="265.3" ederede-arịlịka ="ngwucha" font-size ="11" juru ="Agba ugbu a" opacity="0.8"><otu x ="136.0" dy="0">Opekempe kwa afọ</tsp></ederede> <ahịrị x1="145" y1="261.3" x2="254.5" y2="261.3" ọrịa strok ="Agba ugbu a" opacity="0.15" obosara-strok="1" /> <okirikiri cx="254.5" cy="261.3" r="6" juru ="#nke 78bfa" /> <ederede x ="266.5" y="265.3" font-size ="11" juru ="Agba ugbu a">3</ederede> <ederede x ="280.0" y="366" ederede-arịlịka ="etiti" font-size ="10" juru ="anyi(--chaatị-mechiri emechi, Agba ugbu a)">Isi mmalite: EMA Q&A, EMA/409815/2020 Mkpu.23, Q&A 8 (2025-10-10)</ederede> </svg> </ọgụgụ>
Confirmatory testing is required when the risk evaluation identifies a risk, and it is not expected when the evaluation concludes that no risk is identified. Ntuzi aka nitrosamine nke Canada states that confirmatory testing is not expected where the risk evaluation concludes no risk is identified, na Nitrosamine nke EMA&A (Mkpu.23, October 2025) sets the trigger on the other side: if a risk is identified in the API or the finished product, the MAH must notify the competent authorities and proceed without further delay with confirmatory tests.
A documented no-risk conclusion can be appropriate when the complete product and process assessment supports it. Record assumptions, supplier evidence, contamination controls, formation and purge reasoning, and changes that would reopen the assessment; a negative amine screen alone is insufficient. Spot Peptide Synthesis
Mkpebi nkwenye na mbelata ule na-adabere na ntuziaka dị, tụọ ọkwa, usoro nghọta na agbanwe agbanwe. Ejila obere ntakiri AI dị ala ma ọ bụ otu ụzọ na-adịghị adị ka ikike na-enweghị isi ịhapụ njikwa.. Dekọọ ụdị ntuziaka na ihe akaebe na-eju ọnọdụ ọ bụla.
Ajụjụ a na-ajụkarị
Peptide ọ bụla ọ chọrọ nnwale nitrosamine nkwenye?
Nnwale na-esochi nlebanya ihe egwu akọwapụtara nke ngwaahịa yana atụmanya nhazi ọdabara. Ọnụnọ nke amine naanị adịghị egosi na e guzobere nitrosamine ma ọ bụ na-ekpebi ule na-akpaghị aka. Nyochaa ike nke amine, isi mmalite nitrosating, usoro ọnọdụ, adịghị ọcha, nhazi na nchekwa; nyochaa nkwubi okwu mgbe ozi dị mkpa gbanwere. Onye na-ebu ihe n'ogbe Peptide
Kedu oke oriri anabatara kwesịrị ka onye nrụpụta peptide kwupụta?
Edere onye nọ na ikike ikike faịlụ a, aha ya n'akụkụ nọmba. Ejikọtaghị oke na njedebe dị ala. Tebụl CPCA Health Canada na-esetịpụ udi 1 na 18 nke/ụbọchị, mgbe Tebụl oriri FDA na-anabata maka nitrosamines na-emetụta 26.5 ng/day ruo otu ụdị. Otu 2 site na 5 kwenye na 100, 400, 1,500 na 1,500 nke/ụbọchị. Nkezi nke ngalaba abụọ 1 ụkpụrụ ga-ezighị ezi; họrọ usoro nke na-achịkwa ngwaahịa ahụ wee kwuo ya na faịlụ ahụ. Ebe nitrosamines abụọ dị, Iwu nchikota-oke iwu ahụike Canada gbagoro NDMA gbakwunyere NMBA na 96.0 nke/ụbọchị na NDMA gbakwunyere NDEA na 26.5 nke/ụbọchị, ya mere ọnụ ọgụgụ nke otu-adịghị ọcha abụghị ngụkọta dum.
Kedu ka usoro nitrosamine kwesịrị ịdị nro?
Nwee mmetụta zuru oke iji gosi ọkwa dị n'okpuru ebe ntule dabere na ya, nke bụ akụkụ dị nta nke oke ngwaahịa kpọmkwem karịa oke n'onwe ya. I Q2(R2) chọrọ oke ngụkọ nke usoro adịghị ọcha nke ọnụọgụ ga-adị na ma ọ bụ n'okpuru oke mkpesa., ma kọwapụta oke ahụ dị ka ego kacha ala nke enwere ike ikpebi ya na nkenke na izi ezi dabara adaba. Ụzọ nitrosamine ebipụtara na-erute oke ọnụọgụ n'akụkụ dị ala-kwa-ijeri, mana ọnụ ọgụgụ ndị ahụ sitere na matrices obere molecule. Ọnweghị ọnụ ọgụgụ peptide-matrix a chọtara, ya mere a ga-egosipụta mmetụta uche na matriks nke onye nrụpụta kama ibiri site na akwụkwọ.
Bụ nkwupụta ndị na-ebubata ihe zuru ezu iji mechie ahịrị ihe egwu?
Mba. Nkwupụta bụ ntinye na ntule, ọ bụghị ihe nnọchi anya ya. Ntuzi aka nitrosamine nke Canada na-ekwu na nkwupụta ndị nrụpụta na ndị na-ebubata ngwaahịa anaghị edochi ntule ihe egwu siri ike nke onye nrụpụta, na WHO GMP mgbakwunye na nitrosamines chọrọ ka a nyochaa ụdọ ọkọnọ maka ihe ndị dị ize ndụ. Enweghị ike ịgụta data nitrite ndị na-eweta ihe dị ka oke oke: Nkwuputa njikwa ihe egwu nitrosamine nke ngwaahịa Capsugel na-ekwu na ịsụgharị oriri a na-anakwere n'ime oke mkpokọta ngwaahịa na-adabere na nhazi., ya mere otu ihe oyiyi nitrite pụtara ihe dị iche iche n'ụdị dị iche iche.
Kedu mgbe mgbakwunye nitrosamine ICH M7 ga-abụ nke ikpeazụ?
Ebumnuche atụmatụ ọrụ abụghị ụbọchị nkuchi ejirila n'aka. Lelee ọnọdụ mmezi ICH M7 dị ugbu a yana ntuziaka nitrosamine mpaghara ọdabara mgbe ị na-eme atụmatụ nyocha.
Mmechi
Malite na ngwaahịa na ụzọ, mgbe ahụ nhazi map, mmetọ, ụzọ mbufe na nchekwa. Nyochaa njikwa na ihe akaebe nyocha achọrọ iji kwado nkwubi okwu ọ bụla, akwụkwọ ejighị n'aka nke fọdụrụ ma tọọ ihe na-akpalite nyochagharị.
Ihe ndekọ ahụ bụ ihe na-eme ka nkwubi okwu dịrị ndụ nyochaa. Nlebanya nleba anya ihe egwu CMDh nitrosamine na-akọwa mpaghara, na Ntuzi aka nitrosamine nke Canada na-akọwa njedebe nke ihe ndị na-ebubata akwụkwọ nwere ike ibu. Mepụta ndepụta nyocha ihe egwu nitrosamine gburugburu ubi ndị ahụ, debe LOQ na matriks nke usoro ahụ n'ahịrị ihe ize ndụ ọ na-emechi, ma denye ikike n'ọnụọgụ ọ bụla ị na-ekwu maka oriri anabatara.
Oke abụọ kwesịrị ikwupụta nke ọma. Usoro a na-edepụta nkwubi okwu dị ize ndụ maka peptides arụpụtara kemịkal; ọ naghị edochi nyocha toxicological akọwapụtara nke ngwaahịa. Ma ọ nweghị nitrosamine LOQ ebipụtara nke a tụrụ na matriks nke ọgwụ peptide dị maka edemede a., Ya mere, a ga-emebe usoro nghọta na matriks nke gị kama ịnakwere site na obere akara molekul.. Nzọụkwụ ọzọ: Maapụ Pọtụfoliyo peptide gị ugbu a megide ihuenyo ntinye wee chọpụta ngwaahịa ndị nwere amine na onye mmekọ nitrosating n'otu usoro iyi..
